Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty

Acta Orthopaedica

Volumn 78, Issue 1, 2007, Pages 90-94

  Van Der Heide, Huub J L ^a,b   Rijnberg, Willard J ^b   Van Sorge, Adriaan ^b   Van Kampen, Albert ^a   Schreurs, B Willem ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; INDOMETACIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HETEROTOPIC OSSIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSSIFICATION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TOTAL HIP PROSTHESIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; X RAY FILM;

ADOLESCENT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; INDOMETHACIN; LACTONES; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; SULFONES; TABLETS;

EID: 34147146404     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/17453670610013475     Document Type: Article

References (32)

1. Aspenberg P. Avoid cox inhibitors after skeletal surgery! Acta Orthop Scand 2002; 73: 489-90.
2. Aspenberg P. Drugs and fracture repair. Acta Orthop 2005a; 76: 741-8.
3. Aspenberg P. Postoperative Cox inhibitors and late prosthetic loosening - suspicion increases! Acta Orthop 2005b; 76: 733-4.
4. Banovac K, Williams J M, Patrick L D, Levi A. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord 2004; 42: 707-10.
5. Barthel T, Baumann B, Noth U, Eulert J. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 2002; 73: 611-4.
6. Bischoff R, Dunlap J, Carpenter L, DeMouy E, Barrack R. Heterotopic ossification following uncemented total hip arthroplasty. Effect of the operative approach. J Arthroplasty 1994; 9: 641-4.
7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M B, Hawkey C J, Hochberg M C, Kvien T K, Schnitzer T J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
8. Brooker A F, Bowerman J W, Robinson R A, Riley L H, Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg (Am) 1973; 55: 1629-32.
9. Burd T A, Hughes M S, Anglen J O. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg (Br) 2003; 85: 700-5.
10. Cella J P, Salvati E A, Sculco T P. Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 1988; 3: 229-34.
11. Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004; 306: 384-5.
12. Dahners L E, Mullis B H. Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. J Am Acad Orthop Surg 2004; 12: 139-43.
13. Degner F, Turck D, Pairet M. Meloxicam,Pharmacological, Pharmacokinetic and Clinical Profile. Drugs of today 1998; 34: 1-22.
14. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, Isomaki H, Littlejohn G, Mau J, Papazoglou S. Improvement in gastrointestinal tolerability of the selevtive cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (select) trial in osteoarthritis. Br J Rheumatology 1998; 37: 946-51.
15. Dieppe P A, Ebrahim S, Martin R M, Juni P. Lessons from the withdrawal of rofecoxib. BMJ 2004; 329: 867-8.
16. Dorn U, Grethen C, Effenberger H, Berka H, Ramsauer T, Drekonja T. Indomethacin for prevention of heterotopic ossification after hip arthroplasty. A randomized comparison between 4 and 8 days of treatment. Acta Orthop Scand 1998; 69: 107-10.
17. Eggli S, Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg 2001; 121: 531-5.
18. Feldman M, McMahon A T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43.
19. Gajraj N M. Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96: 1720-38.
20. Grohs J G, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement. A double-blind randomized trial of 100 patients with 1-year followup. Acta Orthop 2007; 78: 95-98.
21. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, Dequeker J, Isomaki H, Littlejohn G, Mau J, Papazoglou S. Gastrointestinal tolerability of Meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatology 1998; 37: 937-45.
22. Knelles D, Barthel T, Karrer A, Kraus U, Eulert J, Kolbl O. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or singledose irradiation. J Bone Joint Surg (Br) 1997; 79: 596-602.
23. Kristensen S S, Pedersen P, Pedersen N W, Schmidt S A, Kjaersgaard-Andersen P. Combined treatment with indomethacin and low-dose heparin after total hip replacement. A double-blind placebo-controlled clinical trial. J Bone Joint Surg (Br ) 1990; 72: 447-9.
24. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32: 25-32.
25. Legenstein R, Bosch P, Ungersbock A. Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 2003; 123: 91-4.
26. Neal B C, Rodgers A, Clark T, Gray H, Reid I R, Dunn L, MacMahon S W. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 2000; 71: 122-8.
27. Romano C L, Duci D, Romano D, Mazza M, Meani E. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 2004; 19: 14-8.
28. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta analysis and systemic review of randomized controlled trials. Am J Med (Suppl 6a) 1999; 107: 48s-54s.
29. Silverstein F E, Faich G, Goldstein J L, Simon L S, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N M, Stenson W F, Burr A M, Zhao W W, Kent J D, Lefkowith J B, Verburg K M, Geis G S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
30. van der Heide H J, Koorevaar R T, Schreurs B W, van Kampen A, Lemmens A. Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplasty 1999; 14: 796-9.
31. van der Heide H J, Spruit M, Slappendel R, Klooster N, van Limbeek J. Prophylaxis for heterotopic ossification after primary total hip arthroplasty. A cohort study between indomethacin and meloxicam. Acta Orthop Belg 2004; 70: 240-6.
32. Weber E, Slappendel R, Durieux M, Dirksen R, van der Heide H, Spruit M. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol 2003; 20: 963-6.